This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

This study has been completed.
Information provided by:
Merz Pharmaceuticals GmbH Identifier:
First received: August 13, 2007
Last updated: March 31, 2009
Last verified: March 2009
Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Condition Intervention Phase
Healthy Drug: Botulinum neurotoxin type A, free of complexing proteins Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double

Resource links provided by NLM:

Further study details as provided by Merz Pharmaceuticals GmbH:

Primary Outcome Measures:
  • Measurement of area

Estimated Enrollment: 30
Study Start Date: August 2007
Study Completion Date: June 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Detailed Description:
Conducted in Europe

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy females, 18 to 65 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00515944

Merz Pharmaceuticals GmbH
Frankfurt am Main, Germany, 61273
Sponsors and Collaborators
Merz Pharmaceuticals GmbH
Study Chair: Merz Pharmaceuticals Merz Pharmaceuticals GmbH
  More Information

Responsible Party: Clinical Pharmacology, Merz Pharmaceuticals Identifier: NCT00515944     History of Changes
Other Study ID Numbers: MRZ 60201-0709/1
Study First Received: August 13, 2007
Last Updated: March 31, 2009

Keywords provided by Merz Pharmaceuticals GmbH:
No condition
healthy volunteers

Additional relevant MeSH terms:
Botulinum Toxins, Type A
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents processed this record on August 21, 2017